Decoding Human T issue Biology to C reate Revolutionary T herapeutics
TRexBio is developing immunoregulatory medicines designed to restore immune balance in autoimmune and inflammatory diseases. By addressing the disease where it presents, in the tissue, our goal is to promote tissue repair for more durable disease control.
Unlocking Precise, Actionable Therapeutic Insights
TRexBio’s Deep Biology Platform is designed to decode regulatory T cell (Treg) function in human tissues, mapping key drivers of immune dysregulation and uncovering targets and insights that inform drug discovery.
Leveraging the platform, we analyze gene expression, pathway activity, and cellular states in disease-relevant human tissue to identify where Treg function is disrupted, including through impaired activation, instability, altered trafficking, or loss of tissue-reparative programs. These insights inform our target selection and translational strategies aligned with underlying disease biology.
The Future of Treg Therapeutics is Here
Our most advanced wholly owned clinical-stage product candidate, TRB-061, is a TNFR2 agonist designed to activate and expand Tregs in inflamed tissues. We are developing TRB-061 for a variety of autoimmune and inflammatory diseases, with an initial focus on moderate-to-severe atopic dermatitis.
Our second wholly owned product candidate, TRB-071, is a CD30 agonist designed to both augment tissue Tregs and block immune inflammatory signaling axes.
In addition to TRB-061 and TRB-071, we are advancing multiple preclinical-stage programs addressing differentiated aspects of tissue Treg biology informed by our proprietary Deep Biology Platform.
We’re Built for Breakthroughs
TRexBio brings together broad expertise across immunology, functional genomics, and clinical development. Our team is united by a shared goal: to bring durable, disease-modifying therapies to patients living with immune-mediated conditions.
We are a team that is better together, welcoming differences in backgrounds, opinions, and experiences.